Bright Minds Biosciences ... (DRUG)
31.42
-1.70 (-5.13%)
At close: Apr 04, 2025, 3:59 PM
31.03
-1.24%
After-hours: Apr 04, 2025, 05:38 PM EDT
-5.13% (1D)
| Bid | 30 |
| Market Cap | 221.32M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -0.14 |
| PE Ratio (ttm) | -224.43 |
| Forward PE | -20.2 |
| Analyst | Buy |
| Ask | 39 |
| Volume | 41,507 |
| Avg. Volume (20D) | 62,188 |
| Open | 32.70 |
| Previous Close | 33.12 |
| Day's Range | 30.25 - 32.78 |
| 52-Week Range | 0.93 - 79.02 |
| Beta | 1.02 |
About DRUG
Bright Minds Biosciences Inc., a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry. The company has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Bra...
Industry Biotechnology
Sector Healthcare
IPO Date Mar 22, 2021
Employees NaN
Stock Exchange NASDAQ
Ticker Symbol DRUG
Website https://brightmindsbio.com
Analyst Forecast
According to 4 analyst ratings, the average rating for DRUG stock is "Buy." The 12-month stock price forecast is $85, which is an increase of 170.53% from the latest price.
Stock Forecasts4 months ago
-1.24%
Bright Minds Biosciences shares are trading higher...
Unlock content with
Pro Subscription
5 months ago
+1.72%
Bright Minds Biosciences shares are trading higher after the company announced a collaboration with Firefly Neuroscience to provide a full analysis of the EEG data in the BREAKTHROUGH study.
